Creating a treatment for severe cannabis-related health issues
Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome
['FUNDING_U01'] · ANEBULO PHARMACEUTICALS, INC. · NIH-10829768
This study is testing a new IV medication that could help people, both adults and kids, who are feeling really sick from using cannabis, by easing their nausea and vomiting in emergency rooms.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ANEBULO PHARMACEUTICALS, INC. (nih funded) |
| Locations | 1 site (LAKEWAY, UNITED STATES) |
| Trial ID | NIH-10829768 on ClinicalTrials.gov |
What this research studies
This research focuses on developing an intravenous medication that blocks the CB1 receptor to help patients suffering from acute cannabinoid intoxication and cannabis hyperemesis syndrome. The approach involves testing this new treatment in emergency settings where patients experience severe nausea, vomiting, and other distressing symptoms after cannabis use. By targeting the CB1 receptor, the research aims to alleviate these symptoms and improve patient outcomes. The study will involve both adult and pediatric patients who present with these conditions in emergency departments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals of all ages who are experiencing acute cannabinoid intoxication or cannabis hyperemesis syndrome.
Not a fit: Patients who do not use cannabis or who have unrelated gastrointestinal issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for individuals experiencing severe reactions to cannabis.
How similar studies have performed: While there has been some research on cannabinoid effects, this specific approach to developing a CB1 antagonist for these acute conditions is novel and has not been extensively tested.
Where this research is happening
LAKEWAY, UNITED STATES
- ANEBULO PHARMACEUTICALS, INC. — LAKEWAY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CUNDY, KENNETH — ANEBULO PHARMACEUTICALS, INC.
- Study coordinator: CUNDY, KENNETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.